Jill Cottel, MD - Treating the Zebras in Primary Care (2017 Conference) (LDN, low dose naltrexone)

In this presentation Dr Cottel shares case studies of patients:

36 year old woman with Ehlers-Danlos Syndrome. This lady was started on Low Dose Naltrexone (LDN) at 1.5mg, increased to 3 mg and found she lost her earlier improvement but on going down to a much lower dose she improved significantly. 

Leonard Weinstock, MD - Celiac Disease (2017 Conference) (LDN, low dose naltrexone)

Celiac disease is a remarkable condition. It can present in so many different ways and have so many symptoms. What we're going to try is to hone down on the autoimmune conditions that are associated with it, which don't get as much attention in the literature as they should.

Leonard Weinstock, MD - Inflammatory Bowel Disease II (2017 Conference) (LDN, low dose naltrexone)

Inflammatory bowel disease is a condition that we see as gastroenterologists on a daily basis. I'm Dr. Weinstock. I'd like to review inflammatory bowel disease, what the traditional approaches are, and some of the newer changes that we've seen with low dose naltrexone. Here are my disclosures.

Laura Dankof, MSN, ARNP, FNP-C 26th June 2019 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: Today, my guest is Laura Dankoff, who is a functional medicine nurse practitioner, speaker, and author. She has her own practice, which is a path to health and healing. Thank you for joining us today, 

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.